In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Patient Engagement Web Platform from ICON Bolsters Clinical Connectivity
An Outsourcing Pharma article featuring commentary from experts EB McLindon & Gretchen Goller, on ICON’s new web-based patient engagement platform to provide patients with study-specific information and connectivity.
-
US Healthcare Reform Scenarios
There is growing interest among politicians and the public for significant change of the US healthcare system, popularising the phrase "Medicare for All". Our Pricing and Market Access team looked at three scenarios based on actual proposals.
-
ICON Introduces New Platform for Potential Trial Participants
A Clinical Trials Arena article featuring commentary from expert EB McLindon, following our announcement of ICON's new patient engagement platform to support people interested in participating in clinical trials by offering study specific information.
-
A New Horizon
A PharmaTimes article featuring commentary from Tom O’Leary on the future of AI in healthcare. O’Leary discusses how the key to maximising AI’s involvement in pharma development is to utilise its ability to draw distinctions and correlations, which would otherwise elude human observation. However, also notes the potential for AI is most exciting when paired with human experience, creativity and instinct.
-
Adopting mHealth Technologies in CV Trials
A Pharmafile article authored by Marie McCarthy and Jack Martin on the use of mHealth technologies in cardiovascular trials. The article discusses how, with the right approach and expert guidance, mHealth can help to collect new types of data, make trials more patient centric (improving recruitment, retention and compliance) and improve operational efficiency.
-
Rare disease trials Q&A
A Pharmaceutical Market Europe (PME) Q&A article authored by Gretchen Goller and Valerie Legrand, discussing the challenges of rare disease trials, including those of recruitment and retention unique to rare disease studies. The article also provides insights on solutions to these challenges.
-
ICER's Growing Impact On Drug Pricing And Reimbursement
Read Forbes' original article referencing the ICON whitepaper ‘The Role of ICER as an Independent HTA Organisation’, exploring how ICER may have a greater impact on payer decision-making than expected and can be viewed as a ‘decision resource’ for budgetary and formulary policy decision making.
-
The rise of patient-centricity
In the April 2019 issue of Pharmaceutical Market Europe (PME), p.32-34, Matt McCarty discusses the importance of understanding what patients value and ways to gather patient insights.
-
ICON CIO – Telemedicine, Wearables & AI Could Boost Clinical Trial Participation
A Diginomica article featuring commentary from ICON's Tom O’Leary, discussing the opportunities for technology to overcome key challenges in clinical trials, such as retention and diversity, by making participation less burdensome for patients.
-
Embracing Digital Health
A thought leadership article by Vicki Anastasi, Matt McCarty and Marie McCarthy, published by the Journal of mHealth, on the skills and expertise needed to best use mHealth to transform clinical trials, thereby improving the efficacy of therapies in the real world and increasing pharma R&D productivity.
